ACON Laboratories Flowflex™ COVID-19 Antigen Home Test

ACON Laboratories Flowflex™ COVID-19 Antigen Home Test

The Flowflex™ COVID-19 Antigen Home Test is a rapid test for the detection of SARS-CoV-2 antigens in anterior nasal specimens. It is intended for self-testing use. For use under an Emergency Use Authorization (EUA) only.
This test uses a nasal swab sample to determine the presence or absence of COVID-19 antigens in nasal samples. This test is authorized for nonprescription home use with self-collected (unobserved) direct anterior nasal (NS) swab specimens from individuals aged 14 years and older or with adult-collected anterior NS samples from individuals aged 2 years or older.

Easy

Easy-to-use nasal swab test

Results

Accurate results in 15 minutes

Safe

Can be used to test children as young as 2 years old

Requires just 1 test

Other COVID-19 antigen home tests may require a 2nd test 2-3 days after the first

Use

For use with and without COVID-19 symptoms

Simple

No need to send off to a lab to obtain results

On-The-Go

Compact packaging for “On-The-Go” testing

Do I have to serial test with the Flowflex COVID-19 Antigen Home Test?

Serial testing is a process in which a user must test themselves twice within a two-to-three-day period. The Flowflex COVID-19 Antigen Home Test has been authorized for use as a single test by individuals with or without symptoms

FDA EUA

Authorization Letter

Healthcare Provider

Package Insert

Consumer

Package Insert

Consumer

Package Insert (Spanish)

Fact Sheet

for Healthcare Professionals

FDA Disclaimer

This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

NEED ORDER AND PRODUCT INFORMATION?

We are here to help! Talk to one of our specialists.